WH Partnership (WHP), with its headquarters in the north east of England, has helped leading gene and cell therapy scientists move closer to developing pioneering products for diseases which currently have no treatment.

WHP, one of the UK’s leading providers of integrated process and cleanrooms, has recently completed Oxford Biomedica’s (OXB) new clean room production facility in Yarnton, Oxford, which manufactures unique gene-based medicines for some of the world’s largest pharmaceutical companies.

Constructed to comply with stringent UK Good Manufacturing Practice (GMP) regulations, the 6,000sq.ft.additional cleanroom space took less than a year from concept to completion and creates extra capacity for existing and potential customers. The facility has just been approved by the Medicines Healthcare Products Regulatory Agency (MHRA) to manufacture bulk drug material for Investigational Medicinal Products (IMPs).

WHP’s managing director, Nigel Hall, said: “We have gained a strong reputation for our cleanroom design and construction in the biotechnology industry and the number and quality of projects that we have in the pipeline continue to grow. We are delighted to have brought our wealth of expertise in stringently-regulated sectors to OXB’s facility and look forward to supporting them in any future expansion plans.”

James Miskin, Chief technical officer of Oxford BioMedica, said: “OXB is delighted with the recent completion of its new GMP clean room production facility in Yarnton. The WHP team worked closely and collaboratively with a small team of OXB in-house experts throughout the project, and WHP’s specific expertise, from detailed design to engineering solutions, was absolutely critical in completing this high quality facility in such a short period of time. This was a very successful construction project which meets with OXB’s exacting quality and technical expectations, and is a testament to the quality and attention to detail within the WHP team.”